{"id":"NCT02727660","sponsor":"Pearl Therapeutics, Inc.","briefTitle":"A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)","officialTitle":"A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-29","primaryCompletion":"2018-04-04","completion":"2018-04-04","firstPosted":"2016-04-04","resultsPosted":"2019-09-26","lastUpdate":"2019-09-26"},"enrollment":1876,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disorder"],"interventions":[{"type":"DRUG","name":"BFF MDI (PT009) 320/9.6 μg","otherNames":["Budesonide and Formoterol Fumarate Inhalation Aerosol"]},{"type":"DRUG","name":"BFF MDI (PT009) 160/9.6 μg","otherNames":["Budesonide and Formoterol Fumarate Inhalation Aerosol"]},{"type":"DRUG","name":"FF MDI (PT005) 9.6 μg","otherNames":["Formoterol Fumarate Inhalation"]}],"arms":[{"label":"BFF MDI (PT009) 320/9.6 μg","type":"EXPERIMENTAL"},{"label":"BFF MDI (PT009) 160/9.6 μg","type":"EXPERIMENTAL"},{"label":"FF MDI (PT005) 9.6 μg","type":"EXPERIMENTAL"}],"summary":"This is a Phase III randomized, double-blind, parallel group, multi-center, 52-week COPD exacerbation and lung function study with PT009 320/9.6 μg, PT009 160/9.6 μg and PT005 9.6 μg, all administered BID.","primaryOutcome":{"measure":"Morning Pre-dose Trough FEV1","timeFrame":"at Week 12","effectByArm":[{"arm":"BFF MDI 320/9.6 ug","deltaMin":0.072,"sd":null},{"arm":"BFF MDI 160/9.6 ug","deltaMin":0.069,"sd":null},{"arm":"FF MDI 9.6 ug","deltaMin":0.037,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":282,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Chile","Denmark","Germany","Italy","Mexico","Norway","Peru","Puerto Rico","Russia","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["35815359"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4138&filename=PT009003_Protocol_Redacted_PDFA.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4138&filename=PT009003_SAP_Redacted_PDFA.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":60,"n":619},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease","Upper respiratory tract infection","Dyspnoea","Headache"]}}